HUMAN CANCER BIOLOGY

Semaphorin 4F as a Critical Regulator of Neuroepithelial Interactions and a Biomarker of Aggressive Prostate Cancer
Yi Ding, Dandan He, Diego Florentin, Anna Frolov, Sue Hilsenbeck, Michael Ittmann, Don Kadmon, Brian Miles, David Rowley, and Gustavo Ayala

Prostate Cancer Progression Correlates with Increased Humoral Immune Response to a Human Endogenous Retrovirus GAG Protein

CANCER THERAPY: PRECLINICAL

Adrenomedullin Blockade Suppresses Growth of Human Hormone–Independent Prostate Tumor Xenograft in Mice
Combined Immunostimulatory Monoclonal Antibodies Extend Survival in an Aggressive Transgenic Hepatocellular Carcinoma Mouse Model
Aizea Morales-Kastresana, Miguel F. Sammamed, Inmaculada Rodriguez, Asis Palazon, Ivan Martinez-Forero, Sara Labiano, Sandra Hervas-Stubbbs, Bruno Sangro, Carmen Ochoa, Ana Rouzaut, Arantza Azpilikueta, Elizabet Bolaños, Maria Jure-Kunkel, Ines Gütgemann, and Ignacio Melero

Glucocorticoid Receptor Antagonism as a Novel Therapy for Triple-Negative Breast Cancer
Maxwell N. Skor, Erin L. Wonder, Masha Kocherginsky, Anju Goyal, Ben A. Hall, Yi Cai, and Suzanne D. Conzen

Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma

Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer
Takeshi Shimamura, Zhao Chen, Margaret Soucheray, Julian Carretero, Eiki Kikuchi, Jeremy H. Tchaicha, Yandi Gao, Katherine A. Cheng, Travis J. Cohoon, Jun Qi, Esra Akbay, Alec C. Kimmelman, Andrew L. Kung, James E. Bradner, and Kwok-Kin Wong

Targeted Nanomedicine for Suppression of CD44 and Simultaneous Cell Death Induction in Ovarian Cancer: An Optimal Delivery of siRNA and Anticancer Drug
Vatsal Shah, Oleh Taratula, Olga B. Garbuzenko, Olena R. Taratula, Lorna Rodriguez-Rodriguez, and Tamara Minko

Combination Therapy with a Second-Generation Androgen Receptor Antagonist and a Metastasis Vaccine Improves Survival in a Spontaneous Prostate Cancer Model
Andressa Ardiani, Benedetto Farsaci, Conni J. Rogers, Andy Prolter, Zhimin Guo, Thomas H. King, David Apelian, and James W. Hodge

Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models
Sara A. Flanigan, Todd M. Pitts, Timothy P. Newton, Gillian N. Kulikowski, Aik Choon Tan, Martine C. McManus, Anna Sprefico, Maria I. Kachaaev, Heather M. Selby, John J. Tentler, S. Gail Eckhardt, and Stephen Leong

JAK1/2 and Pan-Deacetylase Inhibitor Combination Therapy Yields Improved Efficacy in Preclinical Mouse Models of JAK2V617F-Driven Disease
Emeline Evrot, Nicolas Ebel, Vincent Romanet, Claudia Roelli, Rita Andraos, Zhiyan Qian, Arno Diölemeyer, Ernesta Dammassa, Dario Sterker, Robert Cozens, Francesco Hofmann, Masato Murakami, Fabienne Bauffert, and Thomas Radmerski

Molecular Chaperone gp96 Is a Novel Therapeutic Target of Multiple Myeloma
Yunpeng Hua, Shai White-Gilbertson, Joshua Kellner, Saleh Rachidi, Saad Z. Usmani, Gabriela Chiosis, Ronald DePinho, Zihai Li, and Bei Liu

Associations between Single-Nucleotide Polymorphisms in the PI3K–PTEN–AKT–mTOR Pathway and Increased Risk of Brain Metastasis in Patients with Non–Small Cell Lung Cancer
Qianxia Li, Ju Yang, Qianqian Yu, Huanlei Wu, Bo Liu, Huihua Xiong, Guangyuan Hu, Jing Zhao, Xianglin Yuan, and Zhongxing Liao

Validation of a Proliferation-Based Expression Signature as Prognostic Marker in Early Stage Lung Adenocarcinoma
Ignacio I. Wistuba, Carmen Behrens, Francesca Lombardi, Susanne Wagner, Junya Fujimoto, M. Gabriela Raso, Lorenzo Spaggiari, Domenico Galetta, Rayon Riley, Elisha Hughes, Julia Reid, Zaina Sangale, Steven G. Swisher, Neda Kalhor, Cesar A. Moran, Alexander Gutin, Jerry S. Lanchbury, Massimo Barberis, and Edward S. Kim
Promoter Hypomethylation of EpCAM-Regulated Bone Morphogenetic Protein Gene Family in Recurrent Endometrial Cancer
Ya-Ting Hsu, Fei Gu, Yi-Wen Huang, Joseph Liu, Jianhua Ruan, Rui-Lan Huang, Chou-Min Wang, Chun-Liang Chen, Rohit R. Jadhav, Hung-Cheng Lai, David G. Mutch, Paul J. Goodfellow, Ian M. Thompson, Nameer B. Kirma, and Tim Hui-Ming Huang

Bendamustine and Rituximab in Relapsed and Refractory Hairy Cell Leukemia
Mauricio Burotto, Maryalice Stetler-Stevenson, Evgeny Arons, Hong Zhou, Wyndham Wilson, and Robert J. Kreitman

CANCER THERAPY: CLINICAL

A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma

Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer
Robert J. Cardnell, Ying Feng, Lixia Diao, You-Hong Fan, Fatemah Masrorpour, Jing Wang, Yuqiao Shen, Gordon B. Mills, John D. Minna, John V. Heymach, and Lauren A. Byers

Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors
Ferry A.L.M. Eskens, Francisco J. Ramos, Herman Burger, James P. O'Brien, Adelaide Piera, Maja J.A. de Jonge, Yoshiharu Mizui, Erik A.C. Wiemer, Maria Josepa Carreras, José Baselga, and Josep Tabernero

Conjunctival Melanomas Harbor BRAF and NRAS Mutations—Letter

LETTERS TO THE EDITOR

Phase I Study of Vismodegib in Children with Recurrent or Refractory Medulloblastoma: A Pediatric Brain Tumor Consortium Study

Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer
Robert J. Cardnell, Ying Feng, Lixia Diao, You-Hong Fan, Fatemah Masrorpour, Jing Wang, Yuqiao Shen, Gordon B. Mills, John D. Minna, John V. Heymach, and Lauren A. Byers

Conjunctival Melanomas Harbor BRAF and NRAS Mutations—Response
Klaus G. Griewank, Henrike Westekemper, Bastian Schilling, Elisabeth Livingstone, Tobias Schimming, Antje Sucker, Uwe Hillen, Klaus-Peter Steuhl, Lisa Zimmer, and Dirk Schadendorf

AC icon indicates Author Choice
CME icon indicates that this article is available for continuing medical education credit at http://cme.aacrjournals.org
For more information please visit www.aacrjournals.org
ABOUT THE COVER

Cellular internalization of siRNA (red fluorescence) delivered by the nanocarrier (green fluorescence) specifically targeted to cancer cells. Superimposition of red (siRNA) and green (nanocarrier) fluorescence images gives yellow color. For details, see the article by Shah and colleagues on page 6193 of this issue.